Condition
NSCLC (Non-small Cell Lung Cancer)
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 57 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
57 shownBright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint BlockadeNCT07661966 · 2026-10-03
RECRUITINGA Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid TumorsNCT07814248 · 2026-09-02
RECRUITINGReal World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung CancerNCT07806604 · 2026-09-01
RECRUITINGA Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D MutationNCT07668752 · 2026-07-27
RECRUITINGOral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLCNCT07754812 · 2026-06-25
RECRUITINGHypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCNCT07609121 · 2026-06-01
RECRUITINGSerplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%NCT07596121 · 2026-05-13
RECRUITINGMicrowave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy FailureNCT07528274 · 2026-05-01
RECRUITINGA Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCNCT07462377 · 2026-03-31
RECRUITINGNeoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)NCT07354061 · 2026-03-25
RECRUITINGPralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsNCT07704658 · 2026-03-04
RECRUITINGEarly Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1NCT07122258 · 2026-03-01
RECRUITING177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 · 2026-02-23
RECRUITINGSingle-Fraction Pulmonary Ablative Radiotherapy Outcomes and Quality-of-life WorkupNCT07441941 · 2026-01-14
RECRUITINGWAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLCNCT07330050 · 2025-12-01
RECRUITINGTargeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLCNCT07742332 · 2025-11-25
RECRUITINGAdaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)NCT07120698 · 2025-11-05
RECRUITINGA Study of GV20-0251 in Advanced or Refractory Solid TumorsNCT07106827 · 2025-09-04
RECRUITINGA Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid TumorsNCT07376707 · 2025-06-12
RECRUITINGA Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionNCT06682793 · 2025-05-22
RECRUITINGStudy of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)NCT06881784 · 2025-05-06
RECRUITINGCryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLCNCT06939127 · 2025-04-01
RECRUITINGA Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS MutationsNCT06835569 · 2025-03-05
RECRUITINGA Phase I Study of SIM0505 in Participants With Advanced Solid TumorsNCT06792552 · 2025-02-26
RECRUITINGPan-tumor MRD StudyNCT06605404 · 2025-01-08
RECRUITINGD-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLCNCT07016126 · 2024-12-22
RECRUITINGArtificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung CancerNCT06684418 · 2024-12-01
RECRUITINGA Study of AK104 in Subjects With Unresectable Locally Advanced NSCLCNCT06617416 · 2024-11-12
RECRUITINGA Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946NCT06616766 · 2024-10-02
RECRUITINGPhase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLCNCT06863506 · 2024-10-01
RECRUITINGEfficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC PatientsNCT06967532 · 2024-09-06
RECRUITINGStudy of XB010 in Subjects With Solid TumorsNCT06545331 · 2024-08-06
RECRUITINGA Phase 1/1b Study of IAM1363 in HER2 CancersNCT06253871 · 2024-03-25
RECRUITINGCognitive Screening in Lung Cancer PatientsNCT06727370 · 2024-01-10
RECRUITINGA Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid TumorsNCT05592626 · 2023-01-04
RECRUITINGDose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or LymphomasNCT05751798 · 2022-12-20
RECRUITINGThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)NCT04585750 · 2020-10-29
RECRUITINGA Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.NCT07689812 · 2026-12-01
NOT_YET_RECRUITINGNeoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLCNCT07807722 · 2026-09-21
NOT_YET_RECRUITINGStudy of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLCNCT07438600 · 2026-02-24
NOT_YET_RECRUITINGClinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung CancerNCT07285434 · 2026-02-02
ENROLLING_BY_INVITATIONHyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 TrialNCT07274384 · 2026-01-01
NOT_YET_RECRUITINGPhase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLCNCT07242274 · 2025-12-31
NOT_YET_RECRUITINGStereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 TrialNCT07286942 · 2025-12-18
NOT_YET_RECRUITINGSacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI TherapyNCT07193160 · 2025-11-01
NOT_YET_RECRUITINGHigh-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLCNCT07182708 · 2025-10-01
NOT_YET_RECRUITINGPhase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positiveNCT07063329 · 2025-08-08
NOT_YET_RECRUITINGRisk and Prognosis of Brain Metastasis in Non-Small Cell Lung CancerNCT07034365 · 2025-08-01
NOT_YET_RECRUITINGA Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLCNCT06977828 · 2025-07-20
NOT_YET_RECRUITINGA Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNCT05873686 · 2023-10-26
ACTIVE_NOT_RECRUITINGA Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)NCT06015503 · 2023-07-21
ACTIVE_NOT_RECRUITINGObservational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)NCT05520099 · 2023-06-26
ACTIVE_NOT_RECRUITINGObservational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)NCT05478538 · 2023-01-31
ACTIVE_NOT_RECRUITINGA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130 · 2022-11-30
ACTIVE_NOT_RECRUITINGStudy to Evaluate Concordance of Detecting EGFR (Epidermal Growth Factor Receptor) Mutation by Circulating Tumour Free DNA Versus Tissues Biopsy in NSCLC (Non-small Cell Lung Cancer).NCT03562819 · 2018-08-16
COMPLETEDGene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)NCT06876402 · 2013-09-09
ACTIVE_NOT_RECRUITINGA Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer PatientsNCT01639001 · 2012-09-29
COMPLETEDCommon interventions
DocetaxelDRUG5PembrolizumabDRUG3TislelizumabDRUG2177Lu-BetaBartDRUG1A2B395BIOLOGICAL1Adjuvant tislelizumabDRUG1ALTA3263DRUG1apalolimab and toripalimab (QL1706)DRUG1befotertinibDRUG1BetaBart + unlabeled BetaBartDRUG1Bevacizumab injectionDRUG1blood and tissue samplesOTHER1blood and tissue samplesDIAGNOSTIC_TEST1Blood testDIAGNOSTIC_TEST1Bright Light TherapyDEVICE1Cadonilimab (AK104)DRUG1CAROL NSCLC treatment DeviceDEVICE1CemiplimabDRUG1cetuximabDRUG1chemotherapy plus cemiplimabCOMBINATION_PRODUCT1chest enhanced CTDIAGNOSTIC_TEST1Concurrent chemotherapyDRUG1Concurrent RadiochemotherapyCOMBINATION_PRODUCT1Core Needle Biopsy, Forceps Biopsy, Punch BiopsyPROCEDURE1Core Needle, Forceps, or Punch BiopsyPROCEDURE1
Leading sponsors
Tianjin Medical University Cancer Institute and Hospital
4
Fudan University
3
Elephas
2
Pfizer
2
Tang-Du Hospital
2
A2 Biotherapeutics Inc.
1
Akeso
1
Alterome Therapeutics, Inc.
1
AstraZeneca
1
Avistone Biotechnology Co., Ltd.
1
Avistone Pharmaceutical（Ningbo）Co., LTD.
1
Betta Pharmaceuticals Co., Ltd.
1
Biogenea Pharmaceuticals Ltd.
1
EpiBiologics
1
European Institute of Oncology
1
Trial status mix
RECRUITING37
NOT_YET_RECRUITING11
ACTIVE_NOT_RECRUITING6
COMPLETED2
ENROLLING_BY_INVITATION1
Phase mix
PHASE224
PHASE118
PHASE36
NA3
PHASE42
EARLY_PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.